After an antitrust review knocked 2021’s biggest biopharma buyout off course in May, CSL’s $11.7 billion deal for Swiss iron deficiency specialist Vifor Pharma appears to be back on track. Tuesday, ...

CSL’s problems run far deeper than the distraction of sacking a chief executive after the stunning revelation that around half the value of the $US11.7bn ($16.2bn) “transformational” Vifor deal has ...

The global biotechnology company will brief analysts on its latest downgrade on Monday morning after a horror year for the ...

Vifor Pharma, which CSL agreed to buy two days ago in the biggest biopharma M&A deal of the year, is shedding its finished drug manufacturing business to CDMO CordenPharma for an undisclosed price.

Vifor Pharma is losing a chief commercial officer but gaining a new chief medical officer in the form of Sanofi’s Klaus Henning Jensen. Jensen joins from the French Big Pharma where he was its global ...

Vifor, part of Australian group CSL, made the proposal following a two-year investigation by the European Commission. The EU competition enforcer was concerned by Vifor's allegedly misleading ...

ST. GALLEN, Switzerland & HAMBURG, Germany--(BUSINESS WIRE)--Regulatory News: Vifor Pharma and Evotec SE today announced the launch of a 50:50 joint venture focused on the discovery and development of ...

ST. GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News: CSL Limited (ASX: CSL; USOTC:CSLLY) yesterday announced an update regarding the Vifor Pharma AG acquisition. CSL has previously advised that ...

Vifor Pharma has struck a deal to buy a priority review voucher (PRV). The PRV sets Vifor and partner Akebia Therapeutics up to benefit from a fast review at the FDA when they file for approval of ...